Alnylam Pharmaceuticals, Inc. $ALNY Shares Acquired by Allspring Global Investments Holdings LLC

Key Points

• Alnylam Pharmaceuticals saw its shares boosted by 15.2% by Allspring Global Investments, which now holds about 0.24% of the company worth $100.55 million.
• The biopharmaceutical company reported an earnings per share (EPS) of $0.32, significantly beating analysts' estimates of ($0.54), with revenue for the quarter exceeding expectations at $773.69 million.
• Insider trading activity includes sales by EVP Kevin Fitzgerald and CEO Yvonne Greenstreet, who sold shares worth over $5 million combined, indicating a potential shift in ownership dynamics.

Allspring Global Investments Holdings LLC lifted its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 15.2% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 312,216 shares of the biopharmaceutical company's stock after acquiring an additional 41,292 shares during the quarter. Allspring Global Investments Holdings LLC owned about 0.24% of Alnylam Pharmaceuticals worth $100,552,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also made changes to their positions in ALNY. SVB Wealth LLC acquired a new position in shares of Alnylam Pharmaceuticals during the 1st quarter valued at $27,000. Bessemer Group Inc. lifted its holdings in shares of Alnylam Pharmaceuticals by 176.9% during the 1st quarter. Bessemer Group Inc. now owns 108 shares of the biopharmaceutical company's stock valued at $29,000 after acquiring an additional 69 shares in the last quarter. Ameritas Advisory Services LLC acquired a new position in shares of Alnylam Pharmaceuticals during the 2nd quarter valued at $42,000. Washington Trust Advisors Inc. lifted its holdings in shares of Alnylam Pharmaceuticals by 53.5% during the 1st quarter. Washington Trust Advisors Inc. now owns 175 shares of the biopharmaceutical company's stock valued at $47,000 after acquiring an additional 61 shares in the last quarter. Finally, Larson Financial Group LLC lifted its holdings in Alnylam Pharmaceuticals by 77.7% in the 1st quarter. Larson Financial Group LLC now owns 199 shares of the biopharmaceutical company's stock worth $54,000 after buying an additional 87 shares in the last quarter. Institutional investors and hedge funds own 92.97% of the company's stock.

Alnylam Pharmaceuticals Stock Performance

Shares of Alnylam Pharmaceuticals stock opened at $464.95 on Tuesday. The firm has a market cap of $60.95 billion, a PE ratio of -188.24 and a beta of 0.36. The firm's 50-day simple moving average is $452.27 and its 200-day simple moving average is $347.50. The company has a debt-to-equity ratio of 4.10, a quick ratio of 2.75 and a current ratio of 2.80. Alnylam Pharmaceuticals, Inc. has a 1 year low of $205.87 and a 1 year high of $484.21.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last issued its earnings results on Thursday, July 31st. The biopharmaceutical company reported $0.32 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.54) by $0.86. The business had revenue of $773.69 million for the quarter, compared to analyst estimates of $633.54 million. Alnylam Pharmaceuticals had a negative net margin of 12.96% and a negative return on equity of 273.52%. The company's revenue for the quarter was up 17.3% on a year-over-year basis. During the same quarter in the prior year, the business posted ($0.13) EPS. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. Equities analysts forecast that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

Insider Buying and Selling at Alnylam Pharmaceuticals

In related news, EVP Kevin Joseph Fitzgerald sold 2,441 shares of the business's stock in a transaction dated Thursday, October 2nd. The shares were sold at an average price of $452.05, for a total transaction of $1,103,454.05. Following the completion of the sale, the executive vice president owned 25,231 shares of the company's stock, valued at $11,405,673.55. This represents a 8.82% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Yvonne Greenstreet sold 8,924 shares of the business's stock in a transaction dated Thursday, October 2nd. The shares were sold at an average price of $452.05, for a total transaction of $4,034,094.20. Following the sale, the chief executive officer directly owned 65,409 shares of the company's stock, valued at approximately $29,568,138.45. This represents a 12.01% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 98,144 shares of company stock worth $44,160,261. 1.20% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

A number of brokerages have commented on ALNY. Chardan Capital boosted their price objective on shares of Alnylam Pharmaceuticals from $325.00 to $400.00 and gave the stock a "buy" rating in a report on Friday, August 1st. Piper Sandler boosted their price objective on shares of Alnylam Pharmaceuticals from $304.00 to $449.00 and gave the stock an "overweight" rating in a report on Friday, August 1st. Scotiabank boosted their price objective on shares of Alnylam Pharmaceuticals from $342.00 to $450.00 and gave the stock a "sector outperform" rating in a report on Friday, August 1st. Wolfe Research upgraded shares of Alnylam Pharmaceuticals from an "underperform" rating to a "peer perform" rating in a report on Monday, August 4th. Finally, Jefferies Financial Group boosted their price objective on shares of Alnylam Pharmaceuticals from $328.00 to $384.00 and gave the stock a "buy" rating in a report on Monday, July 7th. Twenty-four research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Alnylam Pharmaceuticals currently has a consensus rating of "Moderate Buy" and a consensus target price of $457.08.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.

Want to see what other hedge funds are holding ALNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.